Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

Light at night can increase heart disease risk

Being exposed to bright light at night can significantly increase your chances of developing...

Scientists find new driver of ovarian cancer spread

A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...

Hormone therapy shifts body proteins to match gender identity

Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...

Content from other channels on our network

High-protein concepts on show in Paris

Aussie study of trans fats in packaged food products

Australian Government support for fresh produce suppliers of supermarkets

Best 'young red' awarded to a windswept vineyard in Tassie

Roma Foods celebrates over 70 years of Australian manufacturing

WA Government wants its projects to be built with local green steel

ASC selects Siemens software for Collins Class submarines

Finding efficiencies in creating sustainable jet fuel

DroneShield signs $7.6m US Government deal

Program assists power station workers to find new careers

MSCI report shows rising climate risks

SKF wins at COP30

Submissions wanted for tyre industry inquiry

Researchers to create 'affordable' jet fuel from plant waste

AI may have devastating impact on bees: study